OR WAIT null SECS
April 18, 2024
Article
A new analysis of the REDUCE-IT trial reveals the benefits of icosapent ethyl in reducing cardiovascular outcomes regardless of LDL-C levels.
April 16, 2024
Olezarsen shows promise in managing familial chylomicronemia syndrome, reducing triglycerides and acute pancreatitis events.
April 15, 2024
Laura Ross, PA-C, sits down for a Q&A on the HeartBeet Clinic and the role of reimbursable group visits in cardiovascular disease management and education.
April 11, 2024
Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.
April 10, 2024
A study on a web app for nonprescription statin therapy shows high concordance with clinician assessment, with 84.5% of participants achieving LDL-C reduction of 20% or more.
April 09, 2024
Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.
April 08, 2024
Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.
April 07, 2024
Plozasiran demonstrates a 74% reduction in triglyceride levels at 24 weeks in patients with severe hypertriglyceridemia in the phase 2b SHASTA-2 trial.
April 06, 2024
New data from a phase 3b trial presented at ACC.24 underlines the potential of inclisiran in reducing LDL-C levels among patients with ASCVD.
CSL112 infusion did not reduce major cardiovascular events at 90 days but further analysis suggests patients with elevated LDL-C levels could derive significant benefit.
